Persistent Difficulties in Switching to Second-line ART in Sub-saharan Africa--a Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Dec 31

PMID 24376570

Citations 34

Authors

Yoann Madec

Sandrine Leroy

Marie-Anne Rey-Cuille

Florence Huber

Alexandra Calmy

Affiliations

Soon will be listed here.

Abstract

Objectives: Switching to second-line antiretroviral therapy (ART) largely depends on careful clinical assessment and access to biological measurements. We performed a systematic review and meta-analysis to estimate the incidence of switching to second-line ART in sub-Saharan Africa and its main programmatic determinants.

Methods: We searched 2 databases for studies reporting the incidence rate of switching to second-line ART in adults living in sub-Saharan Africa. Data on the incidence rate of switching were pooled, and random-effect models were used to evaluate the effect of factors measured at the programme level on this incidence rate.

Results: Nine studies (157,340 patients) in 21 countries were included in the meta-analysis. All studies considered patients under first-line ART and conditions to initiate ART were similar across studies. Overall, 3,736 (2.4%) patients switched to second-line ART. Incidence rate of switch was in mean 2.65 per 100 person-years (PY) (95% confidence interval: 2.01-3.30); it ranged from 0.42 to 4.88 per 100 PY and from 0 to 4.80 per 100 PY in programmes with and without viral load monitoring, respectively. No factors measured at the programme level were associated with the incidence rate of switching to second-line ART.

Conclusion: The low incidence rate of switching to second-line ART suggests that the monitoring of patients under ART is challenging and that access to second-line ART is ineffective; efforts should be made to increase access to second-line ART to those in need by providing monitoring tools, education and training, as well as a more convenient regimen.

Citing Articles

Framework for determining the optimal course of action when efficiency and affordability measures differ by perspective in cost-effectiveness analysis-with an illustrative case of HIV treatment in Mozambique.

Corlis J, Zhu J, Macul H, Tiberi O, Boothe M, Resch S Cost Eff Resour Alloc. 2023; 21(1):62.

PMID: 37705101 PMC: 10498553. DOI: 10.1186/s12962-023-00474-4.

Exploring barriers to switching "on time" to second-line antiretroviral therapy among nurses in primary health care facilities, Ekurhuleni Health District, South Africa.

Tenza I, Njuguna C, Sodo P, Ruch A, Francis J, Omole O PLoS One. 2023; 18(4):e0284996.

PMID: 37099552 PMC: 10132530. DOI: 10.1371/journal.pone.0284996.

Magnitude and Factors Associated with Cytopenia Among Children on Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Science, Sidama Region, Southern Ethiopia.

Mohammed Nuru M, Wube T, Fenta D HIV AIDS (Auckl). 2023; 15:145-155.

PMID: 37033890 PMC: 10075263. DOI: 10.2147/HIV.S403923.

Assessment of HIV viral load monitoring in remote settings in Vietnam - comparing people who inject drugs to the other patients.

Lefrancois L, Nguyen B, Pham T, Le N, Dao H, Tran T PLoS One. 2023; 18(2):e0281857.

PMID: 36802388 PMC: 9942987. DOI: 10.1371/journal.pone.0281857.

A Moving Target: Impacts of Lowering Viral Load Suppression Cutpoints on Progress Towards HIV Epidemic Control Goals.

Rosen J, Reynolds S, Galiwango R, Kigozi G, Quinn T, Ratmann O medRxiv. 2023; .

PMID: 36711720 PMC: 9882556. DOI: 10.1101/2023.01.19.23284804.

References

Keiser O, Chi B, Gsponer T, Boulle A, Orrell C, Phiri S . Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011; 25(14):1761-9. PMC: 3605707. DOI: 10.1097/QAD.0b013e328349822f. View

Rawizza H, Chaplin B, Meloni S, Eisen G, Rao T, Sankale J . Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011; 53(12):1283-90. PMC: 3246873. DOI: 10.1093/cid/cir729. View

Fox M, Van Cutsem G, Giddy J, Maskew M, Keiser O, Prozesky H . Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012; 60(4):428-37. PMC: 3392418. DOI: 10.1097/QAI.0b013e3182557785. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F . Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health. 2009; 14(10):1220-5. PMC: 3722497. DOI: 10.1111/j.1365-3156.2009.02338.x. View

van Zyl G, van der Merwe L, Claassen M, Zeier M, Preiser W . Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol. 2011; 83(10):1764-9. DOI: 10.1002/jmv.22189. View

Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L . Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006; 367(9519):1335-42. DOI: 10.1016/S0140-6736(06)68580-2. View

Babiker A, Gilks C, Munderi P, Kabuye G, Kasirye R, Zalwango E . Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2009; 375(9709):123-31. PMC: 2805723. DOI: 10.1016/S0140-6736(09)62067-5. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

10.

Stadeli K, Richman D . Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2012; 18(1):115-23. PMC: 4295493. DOI: 10.3851/IMP2437. View

11.

Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng A, Tchatchueng Mbougua J, Boyer S . Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis. 2011; 11(11):825-33. DOI: 10.1016/S1473-3099(11)70168-2. View

12.

Orrell C, Harling G, Lawn S, Kaplan R, McNally M, Bekker L . Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007; 12(1):83-8. View

13.

Levison J, Orrell C, Losina E, Lu Z, Freedberg K, Wood R . Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther. 2011; 16(6):853-61. PMC: 3225051. DOI: 10.3851/IMP1819. View

14.

Dagnra A, Vidal N, Mensah A, Patassi A, Aho K, Salou M . High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. J Int AIDS Soc. 2011; 14:30. PMC: 3125306. DOI: 10.1186/1758-2652-14-30. View

15.

Ramadhani H, Thielman N, Landman K, Ndosi E, Gao F, Kirchherr J . Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007; 45(11):1492-8. DOI: 10.1086/522991. View

16.

Reynolds S, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I . Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009; 23(6):697-700. PMC: 2720562. DOI: 10.1097/QAD.0b013e3283262a78. View

17.

Petersen M, van der Laan M, Napravnik S, Eron J, Moore R, Deeks S . Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008; 22(16):2097-106. PMC: 2597677. DOI: 10.1097/QAD.0b013e32830f97e2. View

18.

Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B . Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010; 11(8):510-8. PMC: 4833877. DOI: 10.1111/j.1468-1293.2010.00825.x. View

19.

Palombi L, Marazzi M, Guidotti G, Germano P, Buonomo E, Scarcella P . Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis. 2010; 48(1):115-122. DOI: 10.1086/593312. View

20.

Sanne I, Westreich D, Macphail A, Rubel D, Majuba P, Van Rie A . Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc. 2009; 12:38. PMC: 2811100. DOI: 10.1186/1758-2652-12-38. View